Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
M.L. Shiffman.
Retreatment of patients with chronic hepatitis C.
Hepatology, 36 (2002), pp. S128-S34
[2.]
J.H. Hoofnagle, K.D. Mullen, D.B. Jones, V. Rustgi, A. di Bisceglie, M. Peters, et al.
Treatment of chronic non-A, non-B hepatitis with recombinant human interferon. A preliminary report.
N Engl J Med, 315 (1986), pp. 1575-1578
[3.]
A. Di Bisceglie, P. Martin, C. Kassianides, M. Lisker-Melman, L. Murray, J.G. Waggooner, et al.
JH Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, doubleblind, placebo-controlled trial.
N Engl J Med, 321 (1989), pp. 1506-1510
[4.]
A. Alberti, L. Chemello, F. Noventa, L. Cavalletto, G. de Salvo.
Therapy of hepatitis C: retreatment with alpha interferon.
Hepatology, 26 (1997), pp. 137S-42S
[5.]
Consensus Development Panel.
National Institutes of Health consensus development conference panel statement.
Hepatology, 26 (1997), pp. 2S-10S
[6.]
O. Reichard, G. Norkrans, A. Fryden, J.H. Braconier, A. Sonnerborg, O. Weiland.
Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C.
Lancet, 351 (1998), pp. 83-87
[7.]
J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffmman, W.M. Lee, V.K. Rutsgi, et al.
Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.
N Engl J Med, 339 (1998), pp. 1485-1492
[8.]
M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rutsgi, M. Shiffman, R. Reindollar, et al.
Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial.
Lancet, 358 (2001), pp. 958-965
[9.]
M.W. Fried, M. Shiffman, R. Reddy, C. Smith, G. Marinos, F.L. Goncales, et al.
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
N Engl J Med, 347 (2002), pp. 975-982
[10.]
G.L. Davis, R. Esteban-Mur, V. Rustgi, J. Hoefs, S.C. Gordon, C. Trepo, et al.
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C.
N Engl J Med, 339 (1998), pp. 1493-1499
[11.]
V. Di Marco, P. Almasio, A. Vaccaro, D. Ferraro, P. Parisi, M.G. Cataldo, et al.
Combined treatment of relapse of chronic hepatitis C with high-dose α-2b interferon pus ribavirin for 6 or 12 months.
J Hepatol, 33 (2000), pp. 456-462
[12.]
K.J. Cummings, S.M. Lee, E.S. West, J. Cid-Ruzafa, S.G. Fein, Y. Aoki, et al.
Interferon and ribavirin vs interferon alone in the retreatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.
JAMA, 285 (2001), pp. 193-199
[13.]
S.J. Cheng, P.A. Bonis, J. Lau, N.Q. Pham, J.B. Wong.
Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials.
Hepatology, 33 (2001), pp. 231-240
[14.]
C. Camma, S. Bruno, F. Schepis, O. Lo Iacono, P. Andreone, A.G. Gramenzi, et al.
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: A meta-analysis of individual patient data.
Gut, 51 (2002), pp. 864-869
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
